e-learning
resources
Madrid 2019
Monday, 30.09.2019
Severe pneumonia: epidemiology, mechanisms and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Corticosteroids for community-acquired pneumonia: are we still there?
M. Pereira Catarata (Coimbra, Portugal), G. Gonçalves (Coimbra, Portugal), M. Matos (Coimbra, Portugal), A. Ferreira (Coimbra, Portugal)
Source:
International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Session:
Severe pneumonia: epidemiology, mechanisms and treatment
Session type:
Thematic Poster
Number:
2915
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Pereira Catarata (Coimbra, Portugal), G. Gonçalves (Coimbra, Portugal), M. Matos (Coimbra, Portugal), A. Ferreira (Coimbra, Portugal). Corticosteroids for community-acquired pneumonia: are we still there?. 2915
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Corticosteroids for community-acquired pneumonia: a critical view of the evidence
Source: Eur Respir J 2016; 48: 984-986
Year: 2016
Corticosteroids and community-acquired pneumonia
Source: Annual Congress 2007 - Corticosteroids and respiratory failure
Year: 2007
Corticosteroids in severe pneumonia
Source: Eur Respir J 2008; 32: 259-264
Year: 2008
Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016
Community-acquired pneumonia: severity and antibiotic treatments
Source: ERS Course 2018 - Respiratory Infections
Year: 2018
What is pneumonia?
Source: Breathe, 17 (3) 210087; 10.1183/20734735.0087-2021
Year: 2021
Should steroids be used in community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Mixed community-acquired pneumonia in hospitalised patients
Source: Eur Respir J 2006; 27: 795-800
Year: 2006
Lower respiratory tract infections: when are antibiotics mandatory?
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146
Year: 2004
Low-dose corticosteroids during severe community-acquired pneumonia: end of the story
Source: Eur Respir J 2015; 45: 305-307
Year: 2015
Community-acquired pneumonia: treatment failure and complications
Source: ERS Course 2018 - Respiratory Infections
Year: 2018
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future!
Source: Eur Respir J 2008; 31: 1150-1152
Year: 2008
Should macrolides be given to all patients with community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Community-acquired pneumonia associated with COPD : a special entity ?
Source: Virtual Congress 2020 – Clinical challenges in pneumonia
Year: 2020
COPD: what is the frequency and impact of community-acquired pneumonia?
Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept